2008-06-02 23:45:24 -

www.gilead.com - Gilead Sciences, Inc. Susan Hubbard, 650-522-5715 (Investors) Amy Flood, 650-522-5643 (Media) Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Patent & Trademark Office (PTO) has completed the second of four reexamination proceedings and has confirmed the patentability of U.S. Patent No. 5,922,695, which covers the composition of matter for Viread (tenofovir disoproxil fumarate). On May 20, Gilead announced that the U.S. PTO confirmed the patentability of U.S. Patent No. 6,043,230.

The four U.S. PTO review proceedings were initiated July 2007 in response to a challenge issued by the Public Patent Foundation (PUBPAT) in March 2007 for U.S. Patents No. 5,922,695; 5,977,089; 5,935,946; and 6,043,230. In its request for the reexaminations, PUBPAT claimed that prior art existed

that would have impacted the issuance of the original patents.

"Of the four patents originally under PTO review, this composition of matter patent is the most integral to Viread's novel exclusivity," said Gregg Alton, Senior Vice President and General Counsel. "We are pleased with the PTO's swift analyses and actions, which have confirmed the strength of our patent position."

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including uncertainty related to the expected timing of the U.S. PTO's ruling on the remaining two Viread patents, the risk that the U.S. PTO may narrow or invalidate some or all of the original claims in such patents and the risk of the ultimate enforceability of this patent should it be challenged in a court of law. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Viread is a registered trademark of Gilead Sciences, Inc.

For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.

Review Ongoing for Remaining Two Patents